Zur Kurzanzeige

dc.creatorHerzig D., Studer D., Nakas C.T., Kuenzli C., Stauffer T.P., Hovorka R., Bally L.en
dc.date.accessioned2023-01-31T08:28:09Z
dc.date.available2023-01-31T08:28:09Z
dc.date.issued2021
dc.identifier10.1111/dom.14185
dc.identifier.issn14628902
dc.identifier.urihttp://hdl.handle.net/11615/73962
dc.description.abstractWe retrospectively assessed gluco-regulatory hormones over 10 h (including two meals) of fully automated closed-loop insulin delivery using faster (FA) versus standard insulin aspart (IAsp) in adults with type 2 diabetes [n = 15, age 59 ± 10 years, body mass index 34.5 ± 9.1 kg/m2, glycated haemoglobin 7.7 ± 1.2% (60 ± 13 mmol/mol)]. Plasma concentration of human insulin, IAsp, C-peptide, glucagon, glucagon-like peptide 1, glucose-dependent insulinotropic peptide and peptide tyrosine tyrosine were measured every 15-30 min. Endogenous insulin secretion was calculated using C-peptide deconvolution and exposures to hormones were compared using their mean plasma concentrations. Ten-hour exposure of IAsp was higher with FA versus IAsp (P =.037) in line with the 10% higher insulin requirements to achieve similar glucose control. No significant difference was found for total insulin exposure and endogenous insulin secretion. Similarly, other gluco-regulatory hormones did not significantly differ. In conclusion, the faster pharmacokinetic profile and slightly higher aspart exposure of FA versus IAsp remained without significant effects on endogenous insulin secretion or other gluco-regulatory hormones. Further studies are warranted to explore the metabolic and endocrine effects of novel insulins with accelerated pharmacokinetic properties. © 2020 John Wiley & Sons Ltden
dc.language.isoenen
dc.sourceDiabetes, Obesity and Metabolismen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85091521568&doi=10.1111%2fdom.14185&partnerID=40&md5=2273460330866d6f4914775e5ace880f
dc.subjectC peptideen
dc.subjectgastric inhibitory polypeptideen
dc.subjectglucagonen
dc.subjectglucagon like peptide 1en
dc.subjectglucoseen
dc.subjectglycosylated hemoglobinen
dc.subjecthormoneen
dc.subjecthuman insulinen
dc.subjectinsulin asparten
dc.subjectpeptide YYen
dc.subjectantidiabetic agenten
dc.subjectinsulinen
dc.subjectinsulin asparten
dc.subjectadulten
dc.subjectArticleen
dc.subjectbody massen
dc.subjectclinical articleen
dc.subjectcontrolled studyen
dc.subjectexploratory researchen
dc.subjectfemaleen
dc.subjectglucagon blood levelen
dc.subjecthumanen
dc.subjectinsulin blood levelen
dc.subjectinsulin releaseen
dc.subjectinsulin treatmenten
dc.subjectmaleen
dc.subjectmealen
dc.subjectnon insulin dependent diabetes mellitusen
dc.subjectprotein blood levelen
dc.subjectprotein denaturationen
dc.subjectretrospective studyen
dc.subjectageden
dc.subjectcrossover procedureen
dc.subjectdouble blind procedureen
dc.subjectglucose blood levelen
dc.subjectinsulin dependent diabetes mellitusen
dc.subjectinsulin infusionen
dc.subjectmiddle ageden
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBlood Glucoseen
dc.subjectCross-Over Studiesen
dc.subjectDiabetes Mellitus, Type 1en
dc.subjectDiabetes Mellitus, Type 2en
dc.subjectDouble-Blind Methoden
dc.subjectHumansen
dc.subjectHypoglycemic Agentsen
dc.subjectInsulinen
dc.subjectInsulin Asparten
dc.subjectInsulin Infusion Systemsen
dc.subjectMiddle Ageden
dc.subjectRetrospective Studiesen
dc.subjectBlackwell Publishing Ltden
dc.titleEffect of fully automated closed-loop insulin delivery using faster aspart versus standard aspart on gluco-regulatory hormones in type 2 diabetesen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige